CD8A and neoplasm: Depending on the exposure period to chronic tumor-associated antigens, CD8+ T cells usually progress from full efficiency to partial exhaustion and finally, full exhaustion, accompanied by a gradual reduction in antitumor efficiency and weakened response to therapies targeting immune checkpoint inhibitors (ICIs), such as anti-PD-1 treatment [9, 10].